Singapore-based cancer drug startup AUM Biosciences has raised $27 million in a Series A round co-led by health-focused private equity firm Everlife and SPRIM Global Investments, the investment arm of health consultancy SPRIM.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
